Compounded vs FDA-approved GLP-1s

Why compounded GLP-1s exist

Under U.S. federal law, FDA-registered compounding pharmacies (operating under section 503A) may produce drugs that are listed as in shortage by the FDA, even when an FDA-approved version of the drug exists from a brand-name manufacturer. The unprecedented demand for Wegovy and Zepbound in 2023–2024 led to FDA shortage designations for both semaglutide and tirzepatide, opening the door for compounding pharmacies to produce their own versions in significant volume.

The shortage status has evolved as Novo Nordisk and Eli Lilly expanded manufacturing. As shortage designations are removed, the legal basis for compounding contracts — and FDA enforcement priorities have followed.

What "compounded" actually means

A compounded drug is one prepared by a pharmacy from active pharmaceutical ingredients (APIs) and excipients to fill a specific patient need. Compounding can be patient-specific (503A) or large-scale outsourcing (503B), each with different regulatory requirements. Compounded drugs are not FDA-approved — the agency does not review their efficacy, safety, or manufacturing quality before they reach patients.

What the FDA has flagged

The FDA has issued specific warnings about compounded semaglutide and tirzepatide:

• Salt-form substitutions. Some compounded products have used salt forms (e.g., semaglutide sodium, semaglutide acetate) that are not the form used in the FDA-approved drug. The FDA has stated that these salt forms are different active ingredients, raising questions about identity, efficacy, and safety.
• Dosing errors. Adverse event reports include hospitalizations from dosing errors with compounded products, which often come in vials requiring patient measurement rather than pre-filled pen devices.
• Source-API quality. The FDA has noted that some APIs used by compounding pharmacies originate from sources that have not been inspected to U.S. drug-manufacturing standards.

What may be the same — and what definitely isn't

An FDA-approved Wegovy or Zepbound dose is a finished pharmaceutical product manufactured under cGMP (current Good Manufacturing Practice), with documented identity, purity, potency, and stability. A compounded semaglutide or tirzepatide product may use the same API source — or a different one — and is finished by a compounding pharmacy whose quality systems vary by facility.

What is definitely different:

• Regulatory status. Compounded products have not been FDA-approved.
• Labeling and patient information. The structured labeling and pre-filled-pen devices of approved products provide guardrails against dosing error that vial-based compounded products may not.
• Insurance coverage. Compounded products are generally cash-pay and not covered by insurance.
• Legal liability framework. Adverse events with FDA-approved products fall under one regulatory framework; with compounded products, under a different one.

The economic context

Compounded GLP-1s have been substantially cheaper than brand-name Wegovy or Zepbound — frequently by 3–10x. The cost differential is real and matters for access. The flip side is that the FDA's quality framework is one of the things buyers are paying for in the brand-name price; whether the trade-off is acceptable for any individual patient is a personal decision informed by clinical context.

What about "research peptides"?

A separate category — research-grade peptides sold for "laboratory use only" — exists outside both the approved-drug and compounding-pharmacy frameworks. These are not legal for human use under U.S. law, are not subject to even compounding-level quality oversight, and have produced documented cases of dramatic mismatches between labeled and actual content. The research-peptide market is not the same as the compounding-pharmacy market.

How to evaluate a compounded source

For patients who, in consultation with a prescriber, choose a compounded product, evaluating the source rationally matters. Considerations include:

• Is the pharmacy registered with state and federal authorities (503A) and ideally inspected as a 503B outsourcing facility?
• Does the prescriber have visibility into the pharmacy's quality systems and API sources?
• Is the product in the same form (semaglutide base, not a salt substitute) as the FDA-approved version?
• Is dosing handled in a way that minimizes the risk of error (clear instructions, ideally pre-measured doses)?

Bottom line

The compounded GLP-1 phenomenon is a function of demand outpacing approved-product supply. As the FDA shortage designations resolve, the regulatory pressure shifts. For any individual deciding between FDA-approved and compounded products, the questions are: what's the cost differential, what is the source quality, what is the prescriber's visibility into that source, and what level of regulatory framework do you need? Both options can be reasonable choices in some contexts; both have specific things to be aware of.